Heparina Sódica Sala

Heparina Sódica Sala contains the active ingredient heparin sodium, supplied in an unspecified strength and dosage form. It is a prescription anticoagulant medication used in clinical settings to inhibit clot formation by enhancing antithrombin III activity. Originating from the European Union market, this product belongs to the antithrombotic therapeutic class and is administered via haemodialysis, intra‑arterial, or intravenous routes.

Heparina Sódica Sala is employed in several medical situations where anticoagulation is required. It is commonly selected for its rapid onset and reversible action.

- Anticoagulation during haemodialysis procedures to prevent circuit clotting. - Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism. - Intra‑arterial anticoagulation during interventional cardiology or radiology procedures. - Intravenous anticoagulation in surgical or critical‑care settings to reduce thrombotic risk. - Management of acute coronary syndromes when rapid anticoagulation is indicated.

Heparina Sódica Sala may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common: - Minor bleeding at injection or catheter sites. - Bruising or hematoma formation. - Mild thrombocytopenia (platelet count reduction). - Elevated liver enzymes. - Local irritation or erythema.

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT) with paradoxical clot formation. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Spontaneous spinal or epidural hematoma. - Severe hypotension due to systemic bleeding.

Before using Heparina Sódica Sala, clinicians should assess patient‑specific risk factors and monitor relevant laboratory parameters.

- Verify baseline coagulation tests (aPTT, PT/INR) and platelet count. - Adjust dose in patients with renal or hepatic impairment. - Use cautiously in individuals with a history of bleeding disorders or recent surgery. - Avoid use in patients with known hypersensitivity to heparin or pork products. - Monitor for signs of heparin‑induced thrombocytopenia during therapy. - Counsel pregnant or lactating patients only after risk‑benefit evaluation.

Heparina Sódica Sala can interact with several medications, affecting bleeding risk or anticoagulant efficacy.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or antiplatelet agents that increase bleeding. - High‑dose aspirin or clopidogrel in patients at high hemorrhagic risk.

Use with caution: - Thrombolytic agents (e.g., alteplase) during acute clot dissolution. - Certain antibiotics (e.g., vancomycin) that may potentiate anticoagulant effect. - Hormonal therapies (e.g., estrogen) that affect coagulation balance. - Herbal supplements such as ginkgo biloba or garlic that may increase bleeding tendency.